Fig. 1.Decline in in-hospital mortalitiy after acute myocardial
infarction in relation to scientific advances. The timeline desplays the decline
of in-hospital mortality after acute myocardial infarction over the last century,
along with major advances in reperfusion therapy including inovations in
pharmacotherapy, and in procedure and medical devices [1, 2, 3, 4, 5, 6]. CHAMPION, Cangrelor
Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition;
CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; ESSENCE trial,
Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated
heparin in non–Q-wave Coronary Events; EPIC, Evaluation of 7E3 for the
Prevention of Ischemic Complications Study; GISSI, Italian Group for the Study of
Streptokinase in Myocardial Infarction; GPI, glycoprotein inhibitor;
HORIZONS-AMI, Harmonizing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction; ISAR, The Intracoronary Stenting and Antithrombotic
Regimen trial; ISIS-2, Second International Study of Infarct Survival; LMWH, low
molecular weight heparin; PCI, percutaneous coronary intervention; PLATO,
Platelet Inhibition and Patient Outcomes; SIXTY PLUS, Sixty Plus Reinfarction
Study; TIMI 1, Thrombolysis in Myocardial Infarction 1; TRITON-TIMI 38, Trial to
Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis in Myocardial Infarction.